secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280196
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data
--------------------------------------------------------------------------------

- Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.
- R&D expenses Q3 2025: $28.8M (down $2.4M YoY); G&A expenses: $7.9M (up $0.8M YoY).
- ORIC-944 Phase 1b dose exploration completed; PSA50 in 55% (11/20), PSA90 in 20% (4/20), ctDNA clearance in 59% (10/17) mCRPC patients.
- Provisional RP2Ds selected for ORIC-944 with darolutamide (400mg/600mg QD) and apalutamide (600mg/800mg/1200mg QD).
- Appointed Kevin Brodbeck, PhD as Chief Technical Officer; enozertinib data expected at ESMO Asia Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525280196/0001193125-25-280196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525280196/oric-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer